Press Release

<< Back
Printer Friendly Version View printer-friendly version
Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows:

BIO CEO & Investor Conference
Date:   Monday, February 12, 2018
Forum:   Presentation
Time:   1:30 p.m. ET
Location:   New York
     
SunTrust Robinson Humphrey 4th Annual Orphan Drug Day
Date:   Tuesday, February 13, 2018
Forum:   1x1 Meetings
Location:   New York

A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com

Contacts

Media:
Cristi Barnett  
(617) 401-0113
cristi.barnett@editasmed.com

Investors:
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com

Primary Logo

Editas Medicine, Inc.
Print Page    E-mail Page    RSS    E-mail Alerts